MANNKIND CORP Payments to Acquire Available-for-sale Securities
MANNKIND CORP (MNKD) reported Payments to Acquire Available-for-sale Securities of $3.00 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2021-11-09
- MANNKIND CORP payments to acquire available-for-sale securities for the quarter ending 2021-09-30 was $0.00.
- MANNKIND CORP payments to acquire available-for-sale securities for fiscal 2010 was $4.18M, a 108.90% increase from fiscal 2009.
- MANNKIND CORP payments to acquire available-for-sale securities for fiscal 2009 was $2.00M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 244 month | Payments to Acquire Available-for-sale Securities 247 month | Payments to Acquire Available-for-sale Securities 250 month | Payments to Acquire Available-for-sale Securities 253 month | Payments to Acquire Available-for-sale Securities 256 month | Payments to Acquire Available-for-sale Securities 259 month | Payments to Acquire Available-for-sale Securities 263 month | Payments to Acquire Available-for-sale Securities 265 month | Payments to Acquire Available-for-sale Securities 268 month | Payments to Acquire Available-for-sale Securities 271 month | Payments to Acquire Available-for-sale Securities 275 month | Payments to Acquire Available-for-sale Securities 277 month | Payments to Acquire Available-for-sale Securities 280 month | Payments to Acquire Available-for-sale Securities 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.00M 10-Q · filed 2021-11-09 | ||||||||||||||||
| 2021-06-30 | $3.00M 10-Q · filed 2021-08-11 | |||||||||||||||||
| 2014-09-30 | $796.78M 10-Q · filed 2014-11-10 | |||||||||||||||||
| 2014-06-30 | $796.78M 10-Q · filed 2014-08-11 | |||||||||||||||||
| 2014-03-31 | $796.78M 10-Q · filed 2014-05-12 | |||||||||||||||||
| 2013-12-31 | $796.78M 10-K · filed 2014-03-03 | |||||||||||||||||
| 2013-09-30 | $796.78M 10-Q · filed 2013-11-12 | |||||||||||||||||
| 2013-06-30 | $796.78M 10-Q · filed 2013-08-09 | |||||||||||||||||
| 2013-03-31 | $796.78M 10-Q · filed 2013-05-10 | |||||||||||||||||
| 2012-12-31 | $796.78M 10-K · filed 2013-03-18 | |||||||||||||||||
| 2012-09-30 | $796.78M 10-Q · filed 2012-11-09 | |||||||||||||||||
| 2012-06-30 | $796.78M 10-Q · filed 2012-08-09 | |||||||||||||||||
| 2012-03-31 | $796.78M 10-Q · filed 2012-05-10 | |||||||||||||||||
| 2011-12-31 | $796.78M 10-K · filed 2012-03-15 | |||||||||||||||||
| 2011-09-30 | $796.78M 10-Q · filed 2011-11-04 | |||||||||||||||||
| 2011-06-30 | $796.78M 10-Q · filed 2011-08-04 | |||||||||||||||||
| 2010-12-31 | $4.18M 10-K · filed 2013-03-18 | |||||||||||||||||
| 2009-12-31 | $2.00M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |